Search results
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 15 hours agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
COVID-19 is surging. Time to mask up or get a booster? What a Boise medical expert says
Idaho Statesman McClatchy via AOL· 5 hours agoThe Centers for Disease Control and Prevention recommends everyone 6 months and older get an updated...
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
FOX Business· 4 days agoThe State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection...
Moderna shares rise as Argus lifts price target to $150 By Investing.com
Investing.com· 20 hours agoThe firm's decision follows the U.S. Food and Drug Administration's (FDA) approval of Moderna's...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks via Yahoo Finance· 6 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 21 hours agoBut Moderna expects the lion's share of its sales to come in the second half of 2024. That lines up...
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks· 4 days agoNovavax’s filing is based on guidance from the FDA issued last week, which advised COVID-19 vaccine manufacturers Moderna (MRNA Quick QuoteMRNA - Free Report ...
Kansas sues Pfizer over ‘misleading statements’ about COVID vaccine
The Hill via Yahoo News· 4 days agoThe state of Kansas filed a lawsuit Monday against pharmaceutical company Pfizer, alleging the...
Moderna (NASDAQ:MRNA) Stock Price Down 3.9% After Insider Selling
ETF DAILY NEWS· 1 day agoModerna, Inc. (NASDAQ:MRNA – Get Free Report)’s share price fell 3.9% during trading on Tuesday following insider selling activity. 1,055,980 shares changed hands during mid-day ...
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 5 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...